Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Dissecting the role of hemodynamics in ascending aorta aneurysm development in bicuspid aortic valve disease

EF 2022-23

Résumé
Bicuspid aortic valves (BAVs) are the most prevalent congenital heart defect in adults, affecting around 2% of the global population and causing more fatalities and complications than all other congenital heart abnormalities combined. Patients with a BAV are more prone to have ascending aortic dilatation (AAD) which increases their risk of dissection or rupture of their aorta. It is still uncertain whether bicuspid aortopathy is caused by genetic factors or aberrant blood flow (hemodynamics), although both are likely involved. My project aims to isolate and investigate the effects of hemodynamics on the development of AAD, or aneurysms, in BAV disease. To do so, I will use a novel BAV-AAD mouse model established in our lab. In this model, a small portion of mice with mutated natriuretic peptide receptor 2 are born with BAVs whereas the rest are born with normal tricuspid aortic valves (TAVs). Despite the same genetic background, the BAV mice develop bigger aneurysms than the TAV mice, suggesting the differences are due to disturbed hemodynamics associated with the BAV. I hypothesize that aberrant hemodynamics cause perturbations in the normal aorta proteome to contribute to disease development. I will test this hypothesis using global phosphoproteomic profiling to discover novel proteins and signaling pathways involved in flow-regulated AAD development. Ultimately, I expect these studies will identify biomarkers for disease risk-stratification and new therapeutic targets for improved medical management of the millions of at-risk BAV patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
500274
Name
Guruji Vrushali
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Dissecting the role of hemodynamics in ascending aorta aneurysm development in bicuspid aortic valve disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aneurysm; Ascending Aortic Dilation; Bicuspid Aortic Valve; C-Type Natriuretic Peptide; Congenital Heart Disease; Hemodynamics; Proteomics; Shear Stress
Abstract
Bicuspid aortic valves (BAVs) are the most prevalent congenital heart defect in adults, affecting around 2% of the global population and causing more fatalities and complications than all other congenital heart abnormalities combined. Patients with a BAV are more prone to have ascending aortic dilatation (AAD) which increases their risk of dissection or rupture of their aorta. It is still uncertain whether bicuspid aortopathy is caused by genetic factors or aberrant blood flow (hemodynamics), although both are likely involved. My project aims to isolate and investigate the effects of hemodynamics on the development of AAD, or aneurysms, in BAV disease. To do so, I will use a novel BAV-AAD mouse model established in our lab. In this model, a small portion of mice with mutated natriuretic peptide receptor 2 are born with BAVs whereas the rest are born with normal tricuspid aortic valves (TAVs). Despite the same genetic background, the BAV mice develop bigger aneurysms than the TAV mice, suggesting the differences are due to disturbed hemodynamics associated with the BAV. I hypothesize that aberrant hemodynamics cause perturbations in the normal aorta proteome to contribute to disease development. I will test this hypothesis using global phosphoproteomic profiling to discover novel proteins and signaling pathways involved in flow-regulated AAD development. Ultimately, I expect these studies will identify biomarkers for disease risk-stratification and new therapeutic targets for improved medical management of the millions of at-risk BAV patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Guruji, Vrushali
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~